Compare · MDLN vs PAVM
MDLN vs PAVM
Side-by-side comparison of Medline Inc. (MDLN) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PAVM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 1114.0x PAVM ($39.6M).
- Over the past year, MDLN is down 17.7% and PAVM is down 71.6% - MDLN leads by 53.9 points.
- MDLN has hit the wire 20 times in the past 4 weeks while PAVM has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- Medline Inc.
- PAVmed Inc.
- Price
- $33.52-0.24%
- $5.54-9.54%
- Market cap
- $44.15B
- $39.6M
- 1M return
- -20.14%
- -26.26%
- 1Y return
- -17.67%
- -71.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 0
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest PAVM
- PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by PAVmed Inc.
- SEC Form SCHEDULE 13G filed by PAVmed Inc.
- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
- SEC Form DEF 14A filed by PAVmed Inc.
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by PAVmed Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- SEC Form EFFECT filed by PAVmed Inc.